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Background: EWSR1 rearrangements were first identified in Ewing sarcoma, but the spectrum of EWSR1-rearranged neoplasms
now includes many soft tissue tumour subtypes including desmoplastic small round cell tumour (DSRCT), myxoid liposarcoma
(MLPS), extraskeletal myxoid chondrosarcoma (EMC), angiomatoid fibrous histiocytoma (AFH), clear cell sarcoma (CCS) and
myoepithelial neoplasms. We analysed the spectrum of EWSR1-rearranged soft tissue neoplasms at our tertiary sarcoma centre,
by assessing ancillary molecular diagnostic modalities identifying EWSR1-rearranged tumours and reviewing the results in light of
our current knowledge of these and other Ewing sarcoma-like neoplasms.
Methods:We retrospectively analysed all specimens tested for EWSR1 rearrangements by fluorescence in situ hybridisation (FISH)
and/or reverse transcription–PCR (RT–PCR) over a 7-year period.
Results: There was a total of 772 specimens. FISH was performed more often than RT–PCR (n¼ 753, 97.5% vs n¼ 445, 57.6%). In
total, 210 (27.9%) specimens were FISH-positive for EWSR1 rearrangement compared to 111 (14.4%) that showed EWSR1 fusion
transcripts with RT–PCR. Failure rates for FISH and RT–PCR were 2.5% and 18.0%. Of 109 round cell tumours with pathology
consistent with Ewing sarcoma, 15 (13.8 %) cases were FISH-positive without an identifiable EWSR1 fusion transcript, 4 (3.7%) were
FISH-negative but RT–PCR positive and 4 (3.7%) were negative for both. FISH positivity for DSRCT, MLPS, EMC, AFH and CCS was
86.3%, 4.3%, 58.5%, 60.0% and 87.9%, respectively. A positive FISH result led to diagnostic change in 40 (19.0%) EWSR1-
rearranged cases. 13 FISH-positive cases remained unclassifiable.
Conclusions: FISH is more sensitive for identifying EWSR1 rearrangements than RT–PCR. However, there can be significant
morphologic and immunohistochemical overlap between groups of EWSR1-rearranged neoplasms, with important prognostic
and therapeutic implications. FISH and RT–PCR should be used as complementary modalities in diagnosing EWSR1-rearranged
neoplasms, but as tumour groups harbouring EWSR1 rearrangements are increasingly characterised and because given
translocations involving EWSR1 and its partner genes are not always specific for tumour types, it is critical that these are evaluated
by specialist soft tissue surgical pathologists noting the morphologic and immunohistochemical context. As RT–PCR using
commercial primers is limited to only the most prevalent EWSR1 fusion transcripts, the incorporation of high-throughput
sequencing technologies into the standard diagnostic repertoire to assess for multiple molecular abnormalities of soft tissue
tumours in parallel (including detection of newly characterised Ewing sarcoma-like tumours) might be the most effective and
efficient means of ancillary diagnosis in future.
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Soft tissue neoplasms are a heterogeneous group unified only by
their differentiation towards various mesenchymal lineages. Their
classification is incomplete and continues to be refined, aided
particularly by several recent molecular advances. A proportion of
soft tissue tumours harbours characteristic, reproducible genetic
abnormalities, including chromosomal translocations that result in
the fusion of two separate genes, of which there are almost 100
uniquely identified in sarcoma (Mertens and Tayebwa, 2014);
molecular techniques are therefore a crucial and routine adjunct to
diagnosis. First observed to be rearranged in Ewing sarcoma
(Aurias et al, 1983), the Ewing sarcoma breakpoint region 1 gene
(EWSR1) on chromosome 22q12 encodes a 656 amino acid nuclear
protein including a carboxy-terminus 87-amino acid RNA-binding
domain (exons 11–13) involved in protein–RNA binding,
transcription and RNA metabolism (Fisher, 2014). Its role in
cancer cell progression is still unclear, although it may play a
critical role in DNA damage response and cell division (Li et al,
2007; Paronetto, 2013). While initially thought specific for Ewing
sarcoma (formerly the Ewing sarcoma/primitive peripheral
neuroectodermal tumour (PNET) family of tumours) (Dockhorn
Dworniczak et al, 1994), characteristic rearrangements between
EWSR1 and partner genes have been documented in both
tumours of mesenchymal and non-mesenchymal lineage, including
desmoplastic small round cell tumour (DSRCT; Ladanyi and
Gerald, 1994; Antonescu et al, 1998), myxoid liposarcoma (MLPS;
Panagopoulos et al, 1996; Dal Cin et al, 1997; Hosaka et al, 2002),
extraskeletal myxoid chondrosarcoma (EMC; Sciot et al, 1995;
Clark et al, 1996), angiomatoid fibrous histiocytoma (AFH; Hallor
et al, 2005; Rossi et al, 2007; Thway and Fisher, 2015; Thway et al,
2015b), clear cell sarcoma of soft tissue (CCS; Hisaoka et al, 2008;
Wang et al, 2009) and clear cell sarcoma-like tumours of the
gastrointestinal tract (CCSLGT; Thway and Fisher, 2012; Wang
and Thway, 2015), primary pulmonary myxoid sarcoma (PPMS;
Thway et al, 2011), myoepithelial tumours of skin, soft tissue and
bone (Antonescu et al, 2010a; Antonescu et al, 2010b; Thway and
Fisher, 2014; Thway et al, 2015a), and more rarely in low-grade
fibromyxoid sarcoma (LGFMS; Lau et al, 2013) and sclerosing
epithelioid fibrosarcoma (SEF; Doyle et al, 2012; Arbajian et al,
2014). EWSR1 rearrangements can be easily detected in the routine
setting by fluorescence in situ hybridisation (FISH) with break-
apart probes, and corresponding fusion transcripts by reverse
transcription–PCR (RT–PCR) studies, usually using commercial
probes and primers respectively. In view of the increasing
prominence of EWSR1 rearrangement in soft tissue neoplasms,
we evaluated the utility of FISH and RT–PCR as ancillary
diagnostic tools in assessing potential EWSR1-rearranged neo-
plasms in today’s current practice, and assessed the spectrum of
EWSR1-rearranged neoplasms at our tertiary centre over the
course of the establishment of the ancillary molecular diagnostics
and molecular cytogenetics services.
MATERIALS AND METHODS
All neoplasms which had FISH and/or RT–PCR performed to
assess for EWSR1 rearrangement or for fusion transcripts
containing EWSR1 were identified from 2008 to 2015 from the
prospectively maintained Royal Marsden Hospital (RMH) mole-
cular genetics and cytogenetics databases (DG and JS). Information
regarding diagnoses, morphology and immunohistochemistry was
found on the matched surgical pathology reports. Prior to EWSR1
rearrangement testing, diagnoses were made from morphology and
immunohistochemistry by one or two (KT and CF) soft tissue
specialist (consultant/attending) pathologists. Tumours with
pathologic features in keeping with an EWSR1-rearranged
neoplasm were tested to confirm diagnosis, as the presence of
EWSR1 fusion transcripts, or of the presence of an EWSR1
rearrangement in the appropriate pathologic and clinical context,
would represent the diagnostic gold standard; tumours with
pathologic features suggestive of an EWSR1-rearranged neoplasm
or in which an EWSR1-rearranged neoplasm could not be excluded
were also tested. Finally, tumours that were difficult to classify
morphologically and immunohistochemically that could concei-
vably represent atypical variants of EWSR1-rearranged neoplasms
were also tested. FISH or RT–PCR tests were requested only by a
consultant/attending soft tissue pathologist, and chosen in light of
the clinical and pathologic picture and tissue availability. Further
diagnostic interpretation was then made according to the results of
ancillary molecular testing. All cases were formalin-fixed and
paraffin-embedded (FFPE) and included both core biopsy and
excision specimens of material biopsied or resected at our centre,
or were external cases that had been sent for review or second
opinion.
For FISH, 2- to 4-mm thick FFPE sections were dewaxed
overnight at 60 1C, treated with hot buffer wash at 80 1C (2–3 h)
then proteolytic enzyme treatment at 37 1C, and finally washed in
distilled water and then an alcohol series before addition of an
EWSR1 break-apart probe (Vysis, Abbott Laboratories Ltd,
Maidenhead, UK). Hybridisation was performed overnight accord-
ing to the manufacturer’s protocols. An extra pressure cooker step
was more recently added, whereby 35ml of antigen retrieval buffer
and 3.5 l of distilled water were brought to a boil in a pressure
cooker, the dewaxed slides added, the pressure raised and the
cooker cooled after five minutes, after which the slides were
washed twice in distilled water before proceeding to the
hybridisation stage (Vroobel et al, 2016). After FISH, images of
the sections were captured using a cooled charged-coupled device
camera. To minimise nuclear truncation artefacts, only nuclei with
at least two EWSR1 signals were evaluated. Overlapping tumour
nuclei were also excluded from evaluation to decrease false-positive
scoring. With this probe used in this study, separated signals that
were at least three signal widths apart were scored as positive.
However, occasional, scattered positive cells are not sufficient for a
case to be classed as positive; laboratory policy is that there should
be at least 5% of evaluable nuclei in at least three high-power fields,
excluding fields with no positive cells present. Overall, a FISH
study was classed as positive if two analysts were in agreement that
the number of nuclei with clearly separated signals was sufficient
without needing a formal count. In very rare cases, a very small
number of abnormal cells was seen and then a third, usually more
senior analyst would give an assessment and a formal count would
be made. If the proportion of typically abnormal cells in three
selected high-power fields constituted less than 5% of the assessable
cells, then this would be either disregarded or it would be reported
with a caveat to say that there were too few cells to support the
diagnosis.
For reverse transcription real-time quantitative–PCR(RQ–PCR),
RNA was extracted from FFPE samples using the RecoverAll Total
Nucleic Acid Extraction kit (Ambion Ltd., Cambridgeshire, UK)
and transcribed into complementary DNA (cDNA) using the
High Capacity cDNA kit (Applied Biosystems, Warrington, UK)
according to the manufacturers’ recommendations. Amplification
of B2M was performed to assess the quality of the RNA as
described previously (Thway et al, 2016). RQ–PCR reactions
were performed to assess for any or all of the following
fusion transcripts: EWSR1-NR4A3, TAF15-NR4A3, EWSR1-FLI1,
EWSR1-ERG, EWSR1-WT1, EWSR1-ATF1 and EWSR1-CREB1).
Primers and probe sequences were adapted from the literature
(Okamoto et al, 2001; Antonescu et al, 2002; Jin et al, 2003;
Hostein et al, 2004; Coindre et al, 2006; Antonescu et al, 2007;
Lewis et al, 2007) (please see Supplementary Table A for the primer
sequences of the tested fusion transcripts) RQ–PCR was performed
on a 7500-Fast real-time PCR system (Applied Biosystems), using
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Universal TaqMan Master Mix (2X) (Applied Biosystems), 300 nM
of each primer, 100 nM of probe, and 5ml of cDNA in a total
volume of 20 ml. Samples were run in duplicate together with a
negative and positive control for each reaction.
RESULTS
A total of 812 specimens from 762 patients were analysed for
EWSR1 rearrangement by either FISH, RT–PCR or both
modalities. After duplicate cases (repeat testing done on the same
specimen) were excluded, 772 specimens were included in our
analysis (Tables 1–3). Routine FISH was performed on 753 (97.5%)
samples, of which 210 (27.9%) were positive for an EWSR1
rearrangement and 524 (69.6%) were negative. The FISH study
failed in 19 (2.5%) cases. RT–PCR was less commonly used
(445 cases, 57.6%). A fusion transcript containing an EWSR1
rearrangement was documented in 111 (24.9%) samples. Testing
failed in 80 (18.0%) cases. Of the 210 FISH-positive cases, RT–PCR
was performed in 174, and a fusion transcript was identified in 99/
174 (56.9%) cases. Subsequent to a positive FISH result, the initial
diagnosis based on morphology and immunohistochemistry was
changed in 40 (19.0%) cases (Supplementary Table B). Most of
these 40 represented diagnostically complex cases of neoplasms in
which there was significant morphologic and immunophenotypic
overlap with other tumours of other lineages or other sarcomas.
Among these, 14 were initially thought to represent small cell
carcinoma and were subsequently changed to a diagnosis of Ewing
sarcoma or DSRCT. Other confounding diagnoses included
differentiating melanoma from clear cell sarcoma and poorly
differentiated synovial sarcoma (which has predominantly round
cell morphology) from Ewing sarcoma. In five FISH-negative cases,
a fusion transcript was identified and also led to a change in the
initial diagnosis. EWSR1 rearrangement testing (FISH and/or
RT–PCR) was performed in 125 undifferentiated neoplasms, of
which 62 were composed of spindle cells, 26 of round cells, 7 of
pleomorphic cells, with the remainder having mixed morphology.
A FISH-positive result was documented in six (4.8%) cases (three
spindle, one round and two of mixed morphology). The most
common diagnoses for neoplasms that were doubly FISH and
RT–PCR negative for EWSR1-rearrangements are shown in
Supplementary Table C.
EWSR1-rearranged neoplasms. Results from FISH and RT–PCR
studies routinely used for EWSR1-rearranged neoplasms are
summarised in Tables 1–3. The great majority of cases suspected
to represent an EWSR1-rearranged neoplasm underwent FISH
analysis. Suspected cases of Ewing sarcoma, DRSCT, CCS,
CCSLGT, PPMS, AFH and EMC were more likely to undergo
RT–PCR testing compared to suspected cases of myoepithelial
neoplasms and LGFMS. Positive concordance rates between FISH
and RT–PCR studies varied between 34.1% and 80.0%. On the
basis of morphology and immunohistochemistry, 109 cases were
diagnosed as probable or possible Ewing sarcoma. In total, 89
(81.7%) cases had a positive FISH test (EWSR1 rearrangement)
(Figure 1A) and 50 (58.1%) had identifiable EWSR1-FLI1 or
EWSR1-ERG fusion transcripts (92.0% and 8.0%, respectively).
EWSR1 fusion transcripts by RT–PCR were not found in 15
(13.8%) FISH-positive cases, with these likely representing rare
variant fusions. Furthermore, 18 cases (16.5%) were FISH-negative;
4 (3.7%) had an identifiable fusion transcript and 4 (3.7%) did not;
RT–PCR failed or was not performed (due to lack of sufficient
material) in the remaining cases. The four cases which were
morphologically and immunohistochemically thought to represent
Ewing sarcoma but which were FISH and RT–PCR negative are
shown in Table 4. All cases comprised hypercellular neoplasms,
generally with prominent mitoses and necrosis, and 3/4 were
composed of uniform or monotonous small, rounded cells with
scanty cytoplasm, with one showing nuclei with moderate or
sometimes marked atypia. All showed at least focal expression of
CD99 and often of neural/ neuroectodermal markers and were
negative for other markers including cytokeratins, desmin, CD34
and haematolymphoid markers. The final interpretations were of
small round cell tumour, possibly Ewing sarcoma with variant
partner gene, or in the case with cellular atypia, of possible atypical
Ewing sarcoma. Clinically, these were all highly aggressive
tumours; three of the four patients with follow up died of
progressive or metastatic disease within 18 months of diagnosis.
Table 1. Comparison of FISH and RT–PCR in EWSR1-rearranged neoplasms
FISH RT–PCR
Total
suspected
cases
based on
histology
and IHC
Samples
tested Positive Negative Failed
Samples
tested Positive Negative Failed
Histology n n % N % n % n % n % n % n % n %
Ewing sarcoma 109 109 100.0 89 81.7 18 16.5 2 1.8 86 78.9 50 58.1 19 22.1 17 19.8
DRSCT 22 22 100.0 19 86.3 3 13.6 0 0.0 15 68.2 11 73.3 1 6.7 3 20.0
Myxoid LPS 24 23 95.8 1 4.3 21 91.3 1 4.3 NA NA NA NA NA NA NA NA
EMC 41 41 100.0 24 58.5 16 39.0 1 2.4 34 82.9 14 41.2 18 52.9 2 5.6
AFH 20 20 100.0 12 60.0 7 35.0 1 5.0 19 95.0 13 68.4 5 26.3 1 5.3
CCS 33 33 100.0 29 87.9 4 12.1 0 0.0 28 84.8 17 60.1 8 28.6 3 10.7
CCSLGT 5 5 100.0 4 80.0 1 20.0 0 0.0 5 100.0 5 100.0 0 0.0 0 0.0
PPMS 2 2 100.0 1 50.0 1 50.0 0 0.0 2 100.0 1 50.0 0 0.0 1 50.0
Myoepithelial neoplasm 42 42 100.0 13 31.0 26 62.0 3 7.1 22 54.4 0 0.0 16 72.7 6 27.3
LGFMS and SEF 19 19 100.0 5 26.3 14 73.7 0 0.0 10 52.6 6 60.0 2 20.0 2 20.0
Abbreviations: AFH¼ angiomatoid fibrous histiocytoma; CCS¼ clear cell sarcoma; CCSLGT¼ clear cell sarcoma-like tumour of the gastrointestinal tract; DSRCT¼desmoplastic small round cell
tumour; EMC¼ extraskeletal myxoid chondrosarcoma; IHC¼ immunohistochemistry; LGFMS¼ low-grade fibromyxoid sarcoma; LPS¼ liposarcoma; NA¼ not applicable; PPMS¼primary
pulmonary myxoid sarcoma; RT–PCR¼ reverse transcription–PCR; SEF¼ sclerosing epithelioid fibrosarcoma.
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The fourth patient had chemotherapy and a below-knee amputa-
tion but was subsequently lost to follow up (Table 4). Among the
22 suspected cases of DRSCT, the FISH positivity rate was high
(86.3%). RT–PCR reliably identified the EWSR1-WT1 transcript in
2 of 3 FISH-negative cases. High FISH positivity rates were also
documented in CCS (87.9%) and CCSLGT (80.0%). A fusion
transcript involving EWSR1-ATF1 or EWSR1-CREB1 was identi-
fied in all cases of CCSLGT diagnosed pathologically. An EWSR1
rearrangement was less prevalent in EMC, AFH, PPMS, myoe-
pithelial neoplasms, LGFMS and SEF. As would be typical, no
fusion transcript involving EWSR1-ATF1 or EWSR1-CREB1 was
found in EWSR1 FISH-positive myoepithelial neoplasms. Among
the EWSR1-negative samples, 29 samples were positive for a FUS
rearrangement either by FISH or RT–PCR: 18 cases were
diagnosed as myxoid liposarcoma, 9 cases as LGFMS and 2 cases
as SEF.
Reliability of FISH and RT–PCR. FISH was the more reliable
ancillary diagnostic test, with a failure rate for FISH of 2.5%
compared with 18.0% for RT–PCR. FISH failure rates remained
Table 2. Concordance of FISH and RT–PCR positivity according to EWSR1-rearranged neoplasm subtype
Positive
FISH;
Positive
RT–PCR
Positive
FISH;
Negative
RT–PCR
Positive
FISH; Failed
RT–PCR
Positive
FISH;
RT–PCR ND
Negative
FISH;
Positive
RT–PCR
Negative
FISH;
Negative
RT–PCR
Negative
FISH; Failed
RT–PCR
Negative
FISH;
RT–PCR ND
Histology
Samples
tested n % n % n % n % n % n % n % n %
Ewing sarcoma 109 45 41.3 15 13.8 12 11.0 17 15.6 4 3.7 4 3.7 5 4.6 5 4.6
DRSCT 22 9 40.9 0 0.0 3 13.6 7 31.8 2 9.1 1 4.5 0 0.0 0 0.0
Myxoid LPS (FISH and
RT–PCR comparison not
possible due to lack of
commercial EWSR1-
DDIT3 primers)
24 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
EMC 41 14 34.1 7 17.1 1 2.4 2 4.9 0 0.0 11 26.8 1 2.4 4 9.8
AFH 20 9 45.0 2 10.0 0 0.0 1 5.0 4 20.0 3 15.0 0 0.0 0 0.0
CCS 33 17 51.5 5 15.2 3 9.1 4 12.1 0 0.0 3 9.1 0 0.0 1 0.03
CCSLGT 5 4 80.0 0 0.0 0 0.0 0 0.0 1 20.0 0 0.0 0 0.0 0 0.0
PPMS 2 1 50.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 50.0 0 0.0
Myoepithelial neoplasm 42 0 0.0 8 19.0 3 7.1 2 4.8 0 0.0 7 16.7 2 4.8 17 40.5
LGFMS and SEF 19 0 0.0 1 5.3 1 5.3 3 15.8 6 31.6 1 5.3 1 5.3 6 31.6
Abbreviations: AFH¼ angiomatoid fibrous histiocytoma; CCS¼ clear cell sarcoma; CCSLGT¼ clear cell sarcoma-like tumour of the gastrointestinal tract; DSRCT¼desmoplastic small round cell
tumour; EMC¼ extraskeletal myxoid chondrosarcoma; LGFMS¼ low-grade fibromyxoid sarcoma; LPS¼ liposarcoma; NA¼ not applicable; ND¼ not done; PPMS¼primary pulmonary myxoid
sarcoma; RT–PCR¼ reverse transcription–PCR; SEF¼ sclerosing epithelioid fibrosarcoma.
Table 3. Results of EWSR1 and other fusion transcript
rearrangements according to histology routinely used at our
centre
Histology Fusion transcript N
Ewing sarcoma EWSR1-FLI1 46 (92.0%)
EWSR1-ERG 4 (8.0%)
DRSCT EWSR1-WT1 11
EMC EWSR1-NR4A3 13 (81.3%)
TAF15-NR4A3 3 (18.8%)
AFH EWSR1-ATF1 3 (23.0%)
EWSR1-CREB1 10 (77.0%)
CCS EWSR1-ATF1 16 (94.1%)
EWSR1-CREB1 1 (5.9%)
CCSLGT EWSR1-ATF1 2 (40.0%)
EWSR1-CREB1 3 (60.0%)
PPMS EWSR1-CREB1 1
Abbreviations: AFH¼ angiomatoid fibrous histiocytoma; CCS¼ clear cell sarcoma;
CCSLGT¼ clear cell sarcoma-like tumour of the gastrointestinal tract; DSRCT¼
desmoplastic small round cell tumour; EMC¼extraskeletal myxoid chondrosarcoma;
PPMS¼primary pulmonary myxoid sarcoma.
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Figure 1. Fluorescence in situ hybridisation for EWSR1 gene
rearrangement, and histology of variant Ewing sarcoma types.
(A) Fluorescence in situ hybridisation using dual-colour
break-apart probes which flank the EWSR1 breakpoint region on
chromosome 22q12. The nucleus of this neoplasm contains separated
(split) red and green signals indicating a rearrangement involving the
EWSR1 gene at 22q12. A fused normal signal is also present, denoting
the site of the EWSR1 gene. (B and C) Ewing sarcoma. These are
examples of Ewing sarcomas with morphologic features that can cause
diagnostic difficulty, particularly as they can show immunophenotypical
overlap with other round cell neoplasms. (B) Ewing sarcoma with a well-
defined nested architecture and areas of cellular discohesion mimicking
alveolar rhabdomyosarcoma; (C) Ewing sarcoma with irregular cellular
nests in prominent desmoplastic stroma, mimicking desmoplastic small
round cell tumour, and (D) large cell Ewing sarcoma. RT–PCR in each
case was diagnostically contributory, as this showed the presence of
EWSR1-FLI1 fusion transcripts diagnostic of Ewing sarcoma.
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relatively constant from 2008 through 2015 and were 2.6%, 1.6%,
3.0%, 0.0%, 1.1%, 2.3%, 4.6% and 0.0%, respectively. RT–PCR
failure rates were much higher (29.3%, 36.4%, 23.5%, 4.2%, 6.7%,
15.1%, 11.6%, 15.3%, respectively) but did improve over time. FISH
was most likely to fail in myoepithelial neoplasms (7.1%) and AFH
(5.0%) compared to other EWSR1-rearranged neoplasms. The
RT–PCR failure rate was highest for Ewing sarcoma (19.8%),
DRSCT (20.0%), PPMS (50.0%), LGFMS and SEF (50.0%).
Although overall FISH testing was more reliable, the additional
RT–PCR testing was useful in identifying a fusion transcript
containing an EWSR1 rearrangement in FISH-negative cases,
particularly for Ewing sarcoma (four cases, 3.6%), DRSCT (two
cases, 9.1%), AFH (four cases, 20.0%), CCSLGT (one case, 20.0%)
and LGFMS and SEF (six cases, 31.6%).
Unclassifiable EWSR1-rearranged neoplasms. The morphologic
and immunohistochemical characteristics of the 13 unclassifiable
EWSR1-rearranged neoplasms are summarised in Table 5. This
separate group of cancers was more likely to be diagnosed in an older
population (median age 55 years, range 11–82 years). There were
no identifiable recurrent morphologic characteristics in this group.
Despite extensive immunohistochemical studies coupled with mor-
phologic analysis, three cases were classified as spindle cell sarcomas,
not otherwise specified, two as possible myoepithelial neoplasms, one
as possible EMC, one as possible solitary fibrous tumour, one as
possible myxoid spindle cell sarcoma with adipocytic differentiation
and the remainder as unclassifiable neoplasms.
DISCUSSION
The two main diagnostic platforms available to routine surgical
pathology laboratories are FISH and RT–PCR, which are most
beneficial when used as complementary modalities. It is now clear
though that the spectrum of gene fusions associated with soft tissue
tumours is far wider than previously anticipated. Our study
exemplifies the widespread nature of EWSR1 rearrangements in
soft tissue tumours and the need to correlate positive molecular
findings with morphology and immunohistochemistry. FISH was
the more frequently used ancillary test for EWSR1-rearranged
neoplasms, often because FISH can be performed with scanty
amounts of material (using sections cut at 1–4 mm thickness),
compared with RT–PCR which initially required sections cut at
20 mm to isolate sufficient RNA (although this is no longer the case,
with 3–5 mm sections now routinely used). Another reason for the
prevalence of FISH is the lack of available PCR primers to identify
rarer fusion variants. Although RT–PCR still has a higher failure
rate than FISH, it is a valuable complementary modality, as
exemplified in a minority of cases where a fusion transcript was
identified while FISH failed or was negative. Plausible explanations
for these results include cases where the percentage of neoplastic
cells was low and therefore below the threshold where FISH could
assign a positive result (i.e., o15% due to a high immune or
stromal component) and the presence of rare translocation
structures, where the signal configuration could not be easily
Table 4. Pathological characteristics of the four cases which were pathologically thought to represent Ewing sarcoma, but which
were negative for both EWSR1 rearrangement with FISH and for EWSR1-FLI1 and EWSR1-ERG fusion transcripts with RT–PCR
Case no. Age/sex/site Clinical features/follow up Pathology
1 40/F/buttock 15 cm buttock primary with inguinal metastases. Resected.
Metastases to inguinal nodes after 9 months; chemotherapy.
Resection and adjuvant radiotherapy. Died of progressive
disease 1 year after diagnosis
Extensively necrotic, cystic and haemorrhagic cellular tumour of
moderately pleomorphic ovoid cells with vesicular nuclei,
prominent nucleoli and scanty cytoplasm. Frequent mitoses and
apoptoses. Focal CD99þ ; all other markers negative, including
CD56, desmin, neurofilament, S100 protein,
AE1/AE3, EMA, CD30, CD45 and TdT
Final interpretation: ‘Undifferentiated malignant neoplasm,
possibly atypical Ewing sarcoma’
2 23/M/pelvis Presented with irritative bladder symptoms and back pain.
Imaging: 15 cm solid mass in posterior pelvis in presacral space.
Chemotherapy and radical radiotherapy. Developed pulmonary
metastases and died of disease 18 months after diagnosis
Partially necrotic cellular tumour of sheets of uniform round cells
with rounded nuclei, prominent nucleoli and scanty, sometimes
clear cytoplasm. Focally moderate to strong positivity for CD99,
with focal CD56 and focal nuclear S100 protein. All other
markers negative, including desmin, SMA, AE1/AE3, EMA,
CD34, NB84, chromogranin, synaptophysin, NSE, CD30, CD45,
CD138 and TdT
Final interpretation: ‘Small round cell tumour. Possibly Ewing
sarcoma with variant partner gene’
3 13/F/leg 3-year history of bilateral leg and foot discomfort. Imaging: soft
tissue mass dorsal to the talus and anterior to ankle joint.
Chemotherapy. Left below-knee amputation after 6 months
Cellular tumour composed of sheets of uniform small cells with
round to oval nuclei without atypia, and focally clear cytoplasm
and occasional macronucleoli. Mitotic index of 4/10 hpf; no
necrosis. Areas of adjacent fibrosis but no osteoid or chondroid
present. Diffuse strong positivity for CD99 and NSE. All other
markers negative, including TLE1, CD56, desmin, SMA,
AE1/AE3, EMA, CD34, chromogranin, synaptophysin, CD45
and TdT
Final interpretation: ‘Small round cell tumour. Possibly Ewing
sarcoma with variant partner gene. Findings not in keeping with
small cell osteosarcoma or mesenchymal chondrosarcoma’
4 22/F/cerebellum Left cerebellar mass. Resected. Regrowth after 1 month;
debulking, chemotherapy and radiotherapy. Further debulking
after 7 months. Chemotherapy but died of disease 10 months
after diagnosis
Cellular malignant neoplasm composed of small to medium-
sized relatively uniform cells with round nuclei, fine dispersed
chromatin, occasional nucleoli and scanty cytoplasm, with some
cytoplasmic clearing. Focal necrosis, as well as mitotic figures
and apoptoses. Focal CD99, FLI1 and EMAþ ; INI1þ ; desmin,
GFAP, chromogranin, synaptophysin, NB84 and ERG
Final interpretation: ‘Small round cell tumour. Possibly Ewing
sarcoma with variant partner gene’
Abbreviations: F¼ female; hpf = high power fields; M¼male; RT–PCR¼ reverse transcription–PCR.
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interpreted as rearranged. While FISH has traditionally been
viewed as the more sensitive test compared with RT–PCR, in some
tumours such as AFH, RT–PCR shows an equal sensitivity, and
may detect cases that are negative with FISH (Thway et al, 2015b).
There has been a reduction in the technical failure rates of both
modalities over time, but notably of RT–PCR. FISH methods
improved with the addition of the extra step described in the
methods section. The improved success rate in RT–PCR, including
with FFPE material from external institutions, is likely multi-
factorial. The only protocol change over time (which started
around 2011) has been the use of 3–5mm FFPE sections (rather
than 20 mm scrolls) and the deparaffinisation on slides rather than
in microcentrifuge tubes. In addition, the greater amount of non-
microdissected tissue used previously may have saturated PCR
columns with paraffin, undigested material or PCR inhibitor
carryover (Vroobel et al, 2016). The increasing success in recent
years of both RT–PCR and FISH has been markedly aided by the
recognition amongst surgical pathology departments of molecular
diagnostics (to assess genetic abnormalities in solid neoplasms with
available targeted therapies) as a critical component of the patient
pathway. This has resulted in widespread improvements from
hospitals in fixing and processing pathologic specimens to optimise
the tissue available for molecular analysis, with increasing
experience of the staff of both surgical pathology and molecular
laboratories (Vroobel et al, 2016).
Given the increasing spectrum of EWSR1-rearranged neo-
plasms, it is clear that the utility and practicality of ancillary
molecular tests need re-evaluation, and it is important that
physicians are aware of the limitations of molecular diagnostic
techniques, including the non-specificity of many gene fusions.
The increasing discovery of characteristic genetic abnormalities in
soft tissue neoplasms has caused a significant challenge for
molecular diagnostics laboratories in maintaining accredited
ancillary tests (van de Rijn et al, 2014), compounded by the low
cost-benefit ratios due to disease rarity (van de Rijn et al, 2014;
Mourtzoukou et al, 2015). It is important not to disregard the value
of immunohistochemistry (Hornick, 2014), which is highly cost-
effective and widely available in standard surgical pathology
Table 5. Pathological characteristics of the 13 unclassifiable cases with positive EWSR1 rearrangement on FISH
Case no. Age/sex/site Pathology
1 33/M/shoulder Fascicular spindle to focally more polygonal cell tumour; moderate to marked atypia. Extensive necrosis and mitoses.
CD34þ in most cells; focal nuclear S100 proteinþ , very focal AE1/AE3, CD99 and EMA
Final interpretation: ‘Sarcoma NOS’
2 47/F/foot Multinodular spindle and polygonal cell tumour. Focal rhabdoid features and hemangiopericytic pattern. bcl-2, INI1 and
focally CD99þ , very focal S100 proteinþ
Final interpretation: ‘Findings not conclusive. Spindle cell sarcoma NOS; possible myoepithelial tumour, MPNST or
extraskeletal myxoid chondrosarcoma’
3 52/M/shoulder Small ovoid cells separated by fibrous septa. Largely solid; focal myxoid change. Focal necrosis and prominent mitoses. Focal
EMA; all other markers negative. Features inconclusive for myoepithelial carcinoma. Some areas resembling EMC
Final interpretation: ‘Malignant neoplasm, unclassifiable’
4 56/M/shoulder Spindle and ovoid cell neoplasm, focal myxoid change, microcyst formation. Focal CD34, bcl-2 and CD99þ
Final interpretation: ‘Findings not conclusive. Some MLPS-like features. Possibly solitary fibrous tumour’
5 11/M/subcutis of
forearm
Moderately circumscribed lesion of plump ovoid and spindle cells with elongated cytoplasmic processes in myxoid stroma.
No significant pleomorphism or necrosis. EMA, INI1 and focal D2-40þ ; claudin-1, cytokeratin and CD34
Final interpretation: Features resembling epithelioid perineurioma but immunophenotype not wholly supportive.
Possible EMC
6 54/M/kidney Fascicular spindle cell tumour; moderate atypia; focal necrosis and prominent mitoses. Focal nuclear S100 protein, AE1/AE3,
CD99, CD56 and CD34þ
Final interpretation: ‘High-grade spindle cell sarcoma’
7 27/M/oropharynx Epithelioid cells with mild atypia in nests in hyalinised or basement membrane-like stroma; basaloid cells also present. Diffuse
strong MNF116, EMA, CK5/6, CK14 and p63þ . CD10 and calponinþ in peripheral cells
Final interpretation: ‘Probable myoepithelial neoplasm without identifiable partner gene’
8 57/F/neck Small to medium-sized epithelioid and polygonal cells with spindle cell areas. Up to one mitotic figure in 50 high power fields.
Possible foci of adipocytes. Diffuse nuclear S100 protein and p16þ ; focal desmin and GFAPþ . INI1þ
Final interpretation: ‘Borderline tumour which cannot be conclusively characterised’
9 69/M/thyroid Polygonal and spindle cell neoplasm. Focal variable FLI1, INI1, TLE1, CD56, CD99 and bcl-2þ
Final interpretation: ‘Polygonal and spindle cell tumour of indeterminate (probably mesenchymal) lineage, but not otherwise
classifiable. Does not fit into any specific class of EWSR1-rearranged neoplasm’
10 82/M/neck Focally necrotic polygonal cell tumour. S100 protein, synaptophysin and weak focal EMA and chromograninþ
No detectable EWSR1-CREB1 or EWSR1-ATF1 fusions with RT–PCR. No BRAF mutation detected
11 64/F/not available Focally infiltrative biphasic neoplasm with bland spindle cells and epithelioid component, with occasional mitoses but no
necrosis. Epithelioid component positive for CK7 and EMA
Final interpretation: ‘Possible myoepithelial neoplasm’
12 34/M/spinal cord Infiltrative tumour composed of ovoid cells in irregular cords within fibrous tissue. Focally EMAþ , S100 protein, STAT6
and MUC4
Final interpretation: ‘Benign mesenchymal neoplasm of uncertain lineage. Possibly myoepithelial tumour but
immunophenotype incomplete’
13 60/F/thigh Myxoid spindle cell tumour; prominent myxoid stroma. Areas of adipocytic differentiation (but morphology not in keeping
with myxoid liposarcoma). Occasional mitotic figures; no necrosis. Diffuse S100 protein and p16þ ; weak focal CDK4þ . No
DDIT3 rearrangement with FISH
Final interpretation: ‘Myxoid spindle cell sarcoma with adipocytic differentiation’
Abbreviations: DSRCT¼desmoplastic small round cell tumour; EMC¼ extraskeletal myxoid chondrosarcoma; F¼ female; M¼male; MLPS¼myxoid liposarcoma; MPNST¼malignant
peripheral nerve sheath tumour; RT–PCR¼ reverse transcription–PCR. NB: Full immunopanels (including pancytokeratins, S100 protein, CD34, desmin and SMA) were performed for each case.
Only positive findings are listed in most cases.
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laboratories. Immunohistochemical markers that act as surrogates
for molecular investigations are likely to be more cost-effective and
rapid. For example, Ewing sarcomas with EWSR1-ERG fusions can
be detected with the ERG antibody (Wang et al, 2012), although
this is not specific, as other neoplasms (including vascular
tumours, ERG-related myeloproliferative disorders and prostatic
adenocarcinomas) express ERG (Miettinen et al, 2011).
Although helpful in supporting or confirming diagnoses,
FISH and RT–PCR continue to present limitations, and
this is exemplified by Ewing sarcomas (Figure 1B–D). The
t(11;22)(q24;q12) rearrangement leading to EWSR1-FLI1 fusion
is the commonest (inB85%; Delattre et al, 1992), with about 10%
harbouring t(21;22)(q22;q12) leading to EWSR1-ERG fusion
(Sorensen et al, 1994; Maire et al, 2008). However, as there are
numerous variant fusions (present in less than 1%), ancillary
molecular analysis can be negative in tumours displaying typical
morphologic and immunohistochemical features of Ewing sar-
coma. These variants include the EWSR1-ETS fusions EWSR1-
ETV1 (Jeon et al, 1995), EWSR1-ETV4 (Kaneko et al, 1996) and
EWSR1-FEV (Peter et al, 1997) and the TET-ETS fusions FUS-ERG
(Ichikawa et al, 1994; Berg et al, 2009) and FUS-FEV (Ng et al,
2007; Fisher, 2014), as well as rare non-TET/ETS fusions
(Mastrangelo et al, 2000; Yamaguchi et al, 2005; Wang et al,
2007; Szuhai et al, 2009; Sumegi et al, 2011; Fisher, 2014) which are
not routinely detected by RT–PCR. Furthermore, a group of
primitive round cell tumours with histologic appearances similar to
Ewing sarcomas remain unclassifiable, lacking specific clinical and
immunohistochemical features and molecular evidence of EWSR1
gene rearrangements or other small round cell tumour-associated
gene rearrangements such as SS18, DDIT3 or FOXO1. FUS can act
as an alternative to EWSR1 in other neoplasms (Ordonez et al,
2009) although this was not routinely requested in the suspected
EWSR1-rearranged neoplasms assessed, as the role and significance
of FUS as an alternative to EWSR1 was not as well known in
previous years.
The most common genetic abnormality in small round cell
tumours lacking EWSR1 rearrangement seems to be the CIC-DUX4
fusion (Italiano et al, 2012), in which CIC on 19q13.2 fuses with
one of the DUX4 retrogenes on 4q35 or 10q26.3 (Antonescu,
2014). CIC-DUX4 fusions have been demonstrated in up to two
thirds of EWSR1 rearrangement-negative undifferentiated round
cell sarcomas of pediatric and young adult patients (Graham et al,
2012; Italiano et al, 2012; Antonescu, 2014), with expression
profiling demonstrating a distinct gene signature and suggesting a
distinct pathogenesis from Ewing sarcoma (Specht et al, 2014).
BCOR-CCNB3-associated round cell neoplasms are also aggressive
neoplasms occurring largely in bone or sometimes the deep soft
tissues of adolescents or young adults, particularly males (Pierron
et al, 2012; Puls et al, 2014). Although there is a range of histologic
appearances, most are composed of undifferentiated small round
cells similar to Ewing sarcomas. Immunohistochemically they
express nuclear CCNB3 (which is thought to be relatively specific),
with most also expressing bcl-2 and approximately two thirds
positive for CD99 and CD117 (Pierron et al, 2012; Puls et al, 2014).
Some of the tumours in the small subset of doubly FISH and
RT–PCR negative ‘Ewing sarcomas’ we identified (Table 4) may
possibly represent these newly classified entities.
Finally, 13 ‘unclassifiable’ neoplasms which did not show typical
histologic or immunohistochemical features of Ewing sarcoma
showed EWSR1 rearrangement with FISH but no identifiable
partner, that is, they did not harbour detectable EWSR1-related
fusion transcripts with the primers available (Table 5) (Figure 2).
Histologically these showed a wide spectrum of architectures and
cell types, including spindle, round and ovoid cells, and none of
these fitted clearly into any particular group of EWSR1-rearranged
neoplasms. The new interpretation offered for these was therefore
usually of a morphological description such as ‘high grade spindle
cell sarcoma.’ These tended to be malignant neoplasms often with
cellular atypia, necrosis and mitotic figures. None of these had
pathologic features typical of CIC-DUX4- or BCOR-CCNB3-
associated sarcomas. It is unclear whether any of these neoplasms
could represent specific, as yet uncharacterised tumour types
harbouring EWSR1 rearrangements with unknown partner genes,
or if these EWSR1 rearrangements might be non-reproducible and
a function of the intrinsic genetic instability of the tumours. It
seems, however, that ‘unclassifiable’ EWSR1-rearranged neoplasms
represent only a small proportion of cases in this study; from these
relatively small numbers there were no identifiably recurrent
morphologic patterns or immunoprofiles, so the hypothesis of
these representing malignant tumours in which EWSR1 rearrange-
ment was present due to inherent genetic instability rather than as
a driver mechanism for pathogenesis appears more likely. Recently,
investigators have highlighted four cases of SMARCB1-deleted
neoplasms of various morphologies (myoepithelial carcinoma,
extrarenal rhabdoid tumour, poorly differentiated chordoma
and proximal-type epithelioid sarcoma) that also demonstrated
EWSR1 abnormalities with FISH, which had initially led to
misinterpretation of these as EWSR1-rearranged tumours (Huang
et al, 2016). FISH had shown heterozygous deletion or unbalanced
split signals for EWSR1, suggesting unbalanced translocations or
rearrangements, but these were in keeping with false-positive
results owing to the proximity of the SMARCB1 and EWSR1
A B
C D
Figure 2. Examples of neoplasms with EWSR1 rearrangement but no
corresponding detectable EWSR1-associated fusion transcripts.
(A and B) This is a cellular spindle cell neoplasm on the foot of an adult
female. Morphologically, this showed nests and sheets of relatively
uniform spindle cells (A) and was immunohistochemically diffusely
positive for S100 protein (B). The pathologic features were consistent with
clear cell sarcoma (of tendons and aponeuroses), but EWSR1-CREB1 and
EWSR1-ATF1 fusion transcripts were undetectable with RT–PCR. This
may be due to rarer variant translocations or fusion transcripts that are not
detectable with commercial primers. (C and D) This is a neoplasm of
sparse to moderate cellularity, composed of patternless distributions of
ovoid cells with fibrillary cytoplasm in prominent myxoid stroma with
many interspersed thin-walled, medium-sized arcuate vessels. Small
numbers of lipoblasts are present (C). While the cells are often bland,
focally there is some cytologic atypia (D), and the features were of a
tumour with adipocytic differentiation that was not wholly in keeping with
myxoid liposarcoma (MLPS). No FUS-DDIT3 fusion transcripts (seen in the
majority of MLPS) were detectable with RT–PCR. While FISH showed an
EWSR1 rearrangement, no DDIT3 rearrangement was identifiable (which
should be present in myxoid liposarcomas with either FUS-DDIT3 or
EWSR1-DDIT3 fusions). Therefore this remained an unclassifiable
adipocytic neoplasm with myxoid stroma.
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genes on chromosome 22, whereby large SMARCB1 deletions
can involve the EWSR1 locus. Care should therefore be taken
in the interpretation of FISH for EWSR1 rearrangement with
INI1-deficient neoplasms, and in general the FISH patterns for
these tumours have been complex, differing from the more
uniform and simple split signals of typical EWSR1-rearranged
neoplasms (Huang et al, 2016).
CONCLUSIONS
This series demonstrates the importance of FISH and RT–PCR as
ancillary diagnostic tools in the diagnosis of EWSR1-rearranged
neoplasms. Although FISH is more sensitive for identifying EWSR1
rearrangements than RT–PCR, and RT–PCR using commercial
primers is limited to only the most prevalent EWSR1 fusion
transcripts, their complementary use is crucial as cases in which
FISH is negative may demonstrate EWSR1-associated fusion
transcripts on RT–PCR. As translocations involving EWSR1 and
its partner genes are often not specific for tumour types and there
is significant morphologic and immunohistochemical overlap
between groups of EWSR1-rearranged neoplasms, it is critical that
ancillary molecular findings are always evaluated in specific clinical
and pathological context. However, it is also clear that the current
routine technologies available in most surgical pathology or
molecular diagnostics laboratories (chiefly the two major platforms
of FISH and RT–PCR) can only help detect a limited number of
fusion genes and these are also low-throughput and labour
intensive. The incorporation of high-throughput sequencing
technologies into the standard diagnostic repertoire to assess for
multiple molecular abnormalities of soft tissue tumours in parallel
(including detection of newly characterised Ewing sarcoma-like
tumours) might be the most effective and efficient means of
ancillary diagnosis in future. This will provide a more definitive
classification of many neoplasms that are currently not formally
diagnosable with the routine methods available, and enable a
specific treatment plan, including entry into appropriate clinical
trials for targeted therapies towards specific genetic abnormalities.
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